AbbVie Reaches Tariff Relief Pact with Trump Administration.

AbbVie has reached a three-year agreement with the Trump administration that includes investing $100 billion in US research, development, and manufacturing over the next decade. In return, the drugmaker will offer lower prices for certain medicines under Medicaid and expand direct-to-patient access through the TrumpRx website. The deal also provides exemptions from some current and future tariffs.